Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ikena Oncology, Inc. (IKNA : NSDQ)
 
 • Company Description   
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.

Number of Employees: 10

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.33 Daily Weekly Monthly
20 Day Moving Average: 58,415 shares
Shares Outstanding: 48.26 (millions)
Market Capitalization: $64.18 (millions)
Beta: 0.50
52 Week High: $1.94
52 Week Low: $0.97
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.31% -3.23%
12 Week 25.47% 5.26%
Year To Date -18.90% -24.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
645 SUMMER STREET SUITE 101
-
BOSTON,MA 02210
USA
ph: 857-273-8343
fax: -
info@ikenaoncology.com http://www.ikenaoncology.com
 
 • General Corporate Information   
Officers
Mark Manfredi - President; Chief Executive Officer and Director
Jotin Marango - Chief Financial Officer; Chief Operating Officer
Owen Hughes - Director
David Bonita - Director
Iain D. Dukes - Director

Peer Information
Ikena Oncology, Inc. (CORR.)
Ikena Oncology, Inc. (RSPI)
Ikena Oncology, Inc. (CGXP)
Ikena Oncology, Inc. (BGEN)
Ikena Oncology, Inc. (GTBP)
Ikena Oncology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45175G108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 48.26
Most Recent Split Date: (:1)
Beta: 0.50
Market Capitalization: $64.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.54
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 35.71%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -30.59
12/31/24 - -32.10
ROA
06/30/25 - -
03/31/25 - -27.55
12/31/24 - -28.88
Current Ratio
06/30/25 - -
03/31/25 - 13.31
12/31/24 - 11.80
Quick Ratio
06/30/25 - -
03/31/25 - 13.31
12/31/24 - 11.80
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.45
12/31/24 - 2.61
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©